Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Status:
Withdrawn
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This Phase II study will use the MTD from a previous Phase I study at the recommended dose
for the combination regimen from the Phase I trial, Doxil 25mg/m2 IV Q 4 weeks and
temsirolimus 25mg IV Q week.